Research from Redeye, Redeye AB

Redeye

Research from Redeye

Redeye AB

Specialists in innovative and fast-growing Nordic companies within Life Science and Technology.

Redeye is the next generation equity research and investment banking company, specialized in Life Science and Technology. We are the leading provider of Corporate Broking and Corporate Finance in these sectors.

Our clients are innovative growth companies in the Nordics and we use a unique Rating model based on a value based investment philosophy. Redeye was founded 1999 in Stockholm and is regulated by the Swedish Financial Authority (Finansinspektionen).

Equity Bottom-Up

Polygiene Group AB develops, manufactures, and sells antimicrobial and odor control solutions for textiles and other surfaces. The company provides a wide range of technologies and treatments for products, serving partners across various categories, such as sports and outdoor, fashion and lifestyle, workwear, hospitality, home, and healthcare. It operates globally and offers its products under the Polygiene brand.

<ul><li>Redeye terminates its coverage of Polygiene and will cease providing research following quarterly reports or other business events for the company.</li><li>Redeye’s fair value range will be inactivated.</li></ul>

Redeye terminates its coverage of Polygiene and will cease providing research following quarterly reports or other business events for the company.Redeye’s fair value range will be inactivated.

Oncopeptides AB is a biotech company that engages in the research, development, and commercialization of targeted therapies for difficult-to-treat hematological diseases. The company's lead product is Pepaxti (melflufen), a peptide-drug conjugate for the treatment of relapsed or refractory multiple myeloma. Oncopeptides' proprietary Peptide Drug Conjugate (PDC) platform is designed to rapidly and selectively deliver cytotoxic agents into cancer cells.

<ul><li>Redeye has published new research on Oncopeptides.</li></ul>

Redeye has published new research on Oncopeptides.

Oncopeptides: PDC Platform Crosses the Blood-Brain Barrier

Ascelia Pharma AB operates as a drug development company. The Company develops medicines and drugs for the treatment of liver metastases and gastric cancer. Ascelia Pharma serves patients in Sweden.

<ul><li>Redeye comments on the minutes from Ascelia’s Type A meeting with the FDA and subsequent conference call.</li></ul>

Redeye comments on the minutes from Ascelia’s Type A meeting with the FDA and subsequent conference call.

Hacksaw AB operates as a B2B iGaming technology platform and game development company. The Company's platform enables rapid development and distribution of in-house and third-party games including digital slots, scratch cards, and instant win games. Hacksaw serves iGaming operators worldwide.

<ul><li>Redeye comments on Hacksaw’s preliminary Q3-result outcome which was below Redeye’s forecasts.</li></ul>

Redeye comments on Hacksaw’s preliminary Q3-result outcome which was below Redeye’s forecasts.

Stille AB is a Sweden-based company that develops, manufactures, and markets medical devices. The company operates through two business segments: Surgical Instruments and Surgical Tables. The Surgical Instruments segment provides a variety of handcrafted, forged surgical instruments for open surgery, with a focus on cardiovascular, and reconstructive and aesthetic plastic surgery. Its products include scissors, forceps, clamps, and retractors. The Surgical Tables segment, also referred to as Patient Positioning, develops and manufactures specialized procedure-specific tables for cardiovascular surgery, gynecology, and urology.

<ul><li>Redeye provides a preview of its estimates ahead of Stille's Q3 2026 results.</li><li>We expect continued strong sales growth, supported by the normalisation of supply-chain conditions and a favourable comparison base, while margins are expected to remain broadly stable sequentially.</li></ul>

Redeye provides a preview of its estimates ahead of Stille's Q3 2026 results.We expect continued strong sales growth, supported by the normalisation of supply-chain conditions and a favourable comparison base, while margins are expected to remain broadly stable sequentially.

Stille (Q3 preview): Sustained growth with margins holding up

Redeye AB

Polygiene: Redeye ceases coverage

Redeye terminates its coverage of Polygiene and will cease providing research following quarterly reports or other business events for the...

Redeye

Oncopeptides: PDC Platform Crosses the Blood-Brain Barrier

Redeye has published new research on Oncopeptides.

Redeye

Ascelia: Our comment on the FDA minutes

Redeye comments on the minutes from Ascelia’s Type A meeting with the FDA and subsequent conference call.

Redeye

Hacksaw: Q3-results below expectations

Redeye comments on Hacksaw’s preliminary Q3-result outcome which was below Redeye’s forecasts.

Redeye

Stille (Q3 preview): Sustained growth with margins holding up

Redeye provides a preview of its estimates ahead of Stille's Q3 2026 results. We expect continued strong sales growth, supported by the...

Redeye